Mon, Oct 09, 2023
Bristol is buying Mirati at a time when the shares are considerably cheaper than they were. Mirati's shares touched a 52-week high of $101.3 apiece on Nov. 28 and are now trading at $60.2.
More >
Fri, Jan 04, 2019
Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world`s largest cancer drug businesses in the biggest pharmaceutical deal ever.
Tue, Nov 14, 2017
Biocon's contract research arm Syngene International has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
